

## 1 - Product and Company Information

ProductName DANTROLENE SODIUM

## 2 - Hazards Identification

### SPECIAL INDICATION OF HAZARDS TO HUMANS AND THE ENVIRONMENT

Not hazardous according to Directive 67/548/EEC.

### 3 - Composition/Information on Ingredients

Product Name	CAS #	EC no	Annex I
DANTROLENE SODIUM	14663-23-1	238-706-8	None
Formula	C14H9N4NaO5		
Molecular Weight	336.2 AMU		
Synonyms	Dantrolene sodium * Dantrium * Dantrolene sodium * F-400 * 2,4-Imidazolidinedione, 1-((5-(4-nitrophenyl)-2-furanyl)methylene)amino-, sodium salt * 1-((5-(4-nitrophenyl)furfurylidene)amino)hydantoin sodium		

## 4 - First Aid Measures

### AFTER INHALATION

If inhaled, remove to fresh air. If breathing becomes difficult, call a physician.

### AFTER SKIN CONTACT

In case of contact, immediately wash skin with soap and copious amounts of water.

### AFTER EYE CONTACT

In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician.

### AFTER INGESTION

If swallowed, wash out mouth with water provided person is conscious. Call a physician.

## 5 - Fire Fighting Measures

### EXTINGUISHING MEDIA

Suitable: Water spray. Carbon dioxide, dry chemical powder, or appropriate foam.

### SPECIAL RISKS

Specific Hazard(s): Emits toxic fumes under fire conditions.

### SPECIAL PROTECTIVE EQUIPMENT FOR FIREFIGHTERS

Wear self-contained breathing apparatus and protective clothing to prevent contact with skin and eyes.

## 6 - Accidental Release Measures

### PROCEDURE(S) OF PERSONAL PRECAUTION(S)

Exercise appropriate precautions to minimize direct contact with skin or eyes and prevent inhalation of dust.

### METHODS FOR CLEANING UP

Sweep up, place in a bag and hold for waste disposal. Avoid raising dust. Ventilate area and wash spill site after material pickup is complete.

## 7 - Handling and Storage

### HANDLING

Directions for Safe Handling: Avoid inhalation. Avoid contact with eyes, skin, and clothing. Avoid prolonged or repeated exposure.

### STORAGE

Conditions of Storage: Keep tightly closed.

## 8 - Exposure Controls / Personal Protection

### ENGINEERING CONTROLS

Safety shower and eye bath. Mechanical exhaust required.

### GENERAL HYGIENE MEASURES

Wash thoroughly after handling.

### PERSONAL PROTECTIVE EQUIPMENT

Respiratory Protection: Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Respiratory protection is not required. Where protection from nuisance levels of dusts are desired, use type N95 (US) or type P1 (EN 143) dust masks.

Hand Protection: Protective gloves.

Eye Protection: Chemical safety goggles.

## 9 - Physical and Chemical Properties

Appearance Physical State: Solid

Property	Value	At Temperature or Pressure
----------	-------	----------------------------

pH N/A

BP/BP Range N/A

MP/MP Range N/A

Flash Point N/A

Flammability N/A

Autoignition Temp N/A

Oxidizing Properties N/A

Explosive Properties N/A

Explosion Limits N/A

Vapor Pressure N/A

Partition Coefficient N/A

Viscosity N/A

Vapor Density N/A

Saturated Vapor Conc. N/A

Evaporation Rate N/A

Bulk Density N/A

Decomposition Temp. N/A

Solvent Content N/A

Water Content N/A

Surface Tension N/A

Conductivity N/A

Miscellaneous Data N/A

Solubility N/A

## 10 - Stability and Reactivity

### STABILITY

Stable: Stable.

Materials to Avoid: Strong oxidizing agents.

### HAZARDOUS DECOMPOSITION PRODUCTS

Hazardous Decomposition Products: Carbon monoxide, carbon dioxide, and nitrogen oxides.

### HAZARDOUS POLYMERIZATION

Hazardous Polymerization: Will not occur

## 11 - Toxicological Information

RTECS NUMBER: MU3875000

### ACUTE TOXICITY

LD50

Oral

Woman

600 mg/kg

Remarks: Liver: Hepatitis (hepatocellular necrosis), diffuse.

Gastrointestinal: Other changes. Gastrointestinal: Nausea or vomiting.

LD50

Oral

Rat

7432 mg/kg

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs, Thorax, or Respiration: Respiratory depression.

LD50

Subcutaneous

Rat

>16 GM/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Rat

>50 MG/KG

LD50

Mouse

1188 mg/kg

LD50

Intraperitoneal

Mouse

534 MG/KG

Remarks: Lungs, Thorax, or Respiration: Respiratory depression.

Behavioral: Ataxia. Behavioral: Muscle weakness.

LD50

Subcutaneous

Guinea Pig

>16 GM/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Dog

>10550 mg/kg

Remarks: Blood: Changes in spleen. Lungs, Thorax, or

Respiration: Dyspnea.

LD50

Subcutaneous

Rat

>16 GM/KG

Remarks: Blood: Changes in spleen. Lungs, Thorax, or

Respiration: Dyspnea.

LD50

Intravenous

Rat

>50 MG/KG

LD50

Subcutaneous

Dog

>50 MG/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Dog

>50 MG/KG

LD50

Subcutaneous

Dog

>50 MG/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Dog

>50 MG/KG

LD50

Subcutaneous

Dog

>50 MG/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Dog

>50 MG/KG

LD50

Subcutaneous

Dog

>50 MG/KG

Remarks: Behavioral: Muscle weakness. Behavioral: Ataxia. Lungs,

Thorax, or Respiration: Respiratory depression.

LD50

Intravenous

Dog

>50 MG/KG

LD50

Subcutaneous

Dog